Repligen (RGEN) PT Lowered to $245 at Stifel
Tweet
Share
E-mailGet Alerts RGEN Hot Sheet
Price: $180.81 +2.52%
Rating Summary:
23 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 13 | New: 20
Rating Summary:
23 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 13 | New: 20
Join SI Premium – FREE
Stifel analyst Daniel Arias lowered the price target on Repligen (NASDAQ: RGEN) to $245.00 (from $275.00) while maintaining a Buy rating.
You May Also Be Interested In
- Unicycive Therapeutics (UNCY) PT Raised to $15 at Benchmark Following Q2 Results
- Hims and Hers (HIMS) PT Lowered to $35 at Barclays
- Repligen (RGEN) call put ratio 1 call to 6.7 puts into share price up before the bell
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
